Compare TransMedics Group Inc (TMDX) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Upstart Holdings Inc — how do they compare? TransMedics Group Inc trades at $86.4 (market cap $3.00B), while Upstart Holdings Inc trades at $26 (market cap $2.52B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | UPST | |
|---|---|---|
Market Cap | $3.00B | $2.52B |
Sector | Technology | Financials |
52-Week High | $150.42 | $68.11 |
52-Week Low | $61.99 | $24.22 |
Enterprise Value | $3.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Upstart Holdings (UPST) trades at $26.98, down 3.81% on the day, reflecting recent bearish momentum amid mixed earnings performance. The stock shows oversold technical signals with an RSI of 18.98, while fundamentals highlight a return to profitability in 2025 with net income of $53.60M on $1.02B revenue. Recent news indicates strategic refocus on personal loans and AI-driven lending growth, though cash flow volatility and high debt levels pose concerns. Analyst consensus remains divided with a $45.00 price target suggesting significant upside potential from current levels.
The outlook for UPST hinges on execution in AI-powered lending expansion and margin improvement, with risks including consumer credit stress and competitive pressures. Institutional sentiment is cautiously optimistic, but investors should monitor debt management and quarterly earnings consistency for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
